Celldex Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€4.97M - Cost of goods sold
€702.70K - Gross profit
€4.27M - SG&A expenses
€35.63M - R&D expenses
€131.22M - EBITDA
-€198.54M - D&A
€2.87M - EBIT
-€201.41M - Interest expenses
€0.00 - EBT
-€171.26M - Tax expenses
€0.00 - Net income
-€171.26M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€2.58M - Changes in working capital
-€6.61M - Operating cash flow
-€159.75M - Capex
€743.03K - Other investing cash flow
-€1.23M - Net investing cash flow
€141.23M - Total cash dividends paid
€0.00 - Issuance of common stock
-€369.62M - Debt repayment
€0.00 - Other financing cash flow
€1.39M - Net financing cash flow
€1.62M - Foreign exchange effects
€0.00 - Net change in cash
-€16.90M - Cash at end of period
€19.77M - Free cash flow
-€159.01M
Balance sheet
- Cash and cash equivalents
€19.77M - Cash and short-term investments
€540.83M - Total receivables
€77.22K - Inventory
€0.00 - Other current assets
€15.42M - Total current assets
€556.33M - Property, plant & equipment
€6.45M - Goodwill
€0.00 - Intangible assets
€23.33M - Long-term investments
€0.00 - Other non-current assets
€7.98M - Total non-current assets
€37.75M - Total assets
€594.09M - Accounts payable
€1.78M - Short-term debt
€1.32M - Other current liabilities
€25.19M - Total current liabilities
€28.28M - Long-term debt
€1.28M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€2.18M - Total non-current liabilities
€3.46M - Total liabilities
€31.75M - Common stock
€56.63K - Retained earnings
-€1.43B - Other equity
€2.86M - Total equity
€562.34M - Total liabilities and shareholders' equity
€594.09M
Company information
- Market capitalization
€1.15B - Employees
186 - Enterprise Value
€1.32B
Company ratios
- Gross margin
-
85.9% Much better than peer group: -54,929,343,136,268.9% - EBITDA margin
-
-3,995.9% Much better than peer group: -302,795,951,863,229.7% - EBIT margin
-
-4,053.7% Much better than peer group: -305,609,415,848,815.6% - EBT margin
-
-3,446.9% Much better than peer group: -305,174,664,451,337.9% - Net margin
-
-3,446.9% Much better than peer group: -305,174,664,525,044.6% - ROE
-
-30.5% Much worse than peer group: 82.1% - ROA
-
-28.8% Much better than peer group: -80.0% - Asset turnover
-
0.8% Worse than peer group: 19.5% - FCF margin
-
-3,230.1% Much better than peer group: -254,260,842,167,868.5% - FCF yield
-14.0% - Efficiency ratio
4,095.9% - Net sales per employee
-
€26.71K - Net income per employee
-
-€920.78K